血液肿瘤基因突变模式与CHIP相关突变及年龄的关联
该研究对28种血液肿瘤共3096例的122个基因进行突变图谱比较分析,发现不同疾病在突变数目、特定突变频率、谱系分布及与年龄的相关性上存在差异。DTA突变(DNMT3A、TET2、ASXL1)阳性病例中RUNX1、SRSF2、IDH2、NRAS、EZH2突变频率较高,DTA阴性病例中TP53、KRAS、WT1、SF3B1更常见。
要点
- 不同血液肿瘤的突变数目和特定基因突变频率差异显著。
- TET2、DNMT3A、ASXL1、TP53等突变与较大年龄相关。
- DTA突变状态与后续突变谱不同,提示病理生理差异。
核心结论
- 血液肿瘤突变图谱在突变数目、特定突变频率、谱系分布及与年龄的相关性上存在疾病间差异。
- DTA突变阳性与阴性病例的伴随突变谱不同,提示病理生理差异,并支持按突变驱动与融合驱动对疾病分类。
研究设计与样本
- 对28种血液肿瘤共3096例进行122个基因的突变图谱比较分析。
- 比较内容涵盖突变数目、特定突变频率、谱系分布、与年龄的相关性及DTA突变状态。
主要发现
- 中位突变数目最高为4,最低为0。
- aCML中ASXL1突变频率86%,FL中KMT2D为87%、CREBBP为73%,HCL中BRAF为100%,LPL中MYD88为98%、CXCR4为51%,MPN中AK2为68%。
- TET2、ASXL1、DNMT3A、TP53、BCOR、ETV6在髓系/淋系中呈广泛分布。
- 与较大年龄相关的突变包括TET2、DNMT3A、ASXL1、TP53、EZH2、BCOR、GATA2、IDH2;与较小年龄相关的包括KIT、POT1、RAD21、U2AF2、WT1。
- 至少含1个DTA突变病例中RUNX1、SRSF2、IDH2、NRAS、EZH2频率较高;无DTA突变病例中TP53、KRAS、WT1、SF3B1更常见。
关键数值与推荐
- 中位突变数目最高为4、最低为0。
- aCML:ASXL1 86%;FL:KMT2D 87%、CREBBP 73%;HCL:BRAF 100%;LPL:MYD88 98%、CXCR4 51%;MPN:AK2 68%。
- 与较大年龄相关的突变:TET2、DNMT3A、ASXL1、TP53、EZH2、BCOR、GATA2、IDH2。
- 与较小年龄相关的突变:KIT、POT1、RAD21、U2AF2、WT1。
临床怎么用
- 可依据疾病特异的突变频率辅助诊断分型,如HCL的BRAF、LPL的MYD88/CXCR4。
- 评估突变时需结合患者年龄及DTA突变状态解读伴随突变谱。
- DTA突变状态有助于理解疾病病理生理并区分突变驱动与融合驱动实体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acquired somatic mutations are crucial for the development of most cancers. We performed a comprehensive comparative analysis of the mutational landscapes and their correlation with CHIP-related (clonal hematopoiesis of indeterminate potential) mutations and patient age of 122 genes in 3096 cases of 28 different hematological malignancies. Differences were observed regarding (1) the median number of mutations (highest, median n = 4; lowest, n = 0); (2) specificity of certain mutations (high frequencies in atypical chronic myeloid leukemia [aCML; ASXL1, 86%], follicular lymphoma [FL; KMT2D, 87%; CREBBP, 73%], hairy cell lymphoma [BRAF, 100%], lymphoplasmacytic lymphoma [MYD88, 98%; CXCR4, 51%], myeloproliferative neoplasm [MPN; AK2, 68%]); (3) distribution of mutations (broad distribution within/across the myeloid/lymphoid lineage for TET2, ASXL1, DNMT3A, TP53, BCOR, and ETV6); (4) correlation of mutations with patient's age (correlated with older age across entities: TET2, DNMT3A, ASXL1, TP53, EZH2, BCOR, GATA2, and IDH2; younger age: KIT, POT1, RAD21, U2AF2, and WT1); (5) correlation of mutation number per patient with age. Moreover, we observed high frequencies of mutations in RUNX1, SRSF2, IDH2, NRAS, and EZH2 in cases comprising at least 1 DTA (DNMT3A, TET2, ASXL1) mutation, whereas in cases without DTA mutations, TP53, KRAS, WT1, and SF3B1 were more frequent across entities, suggesting differences in pathophysiology. These results give further insight into the complex genetic landscape and the role of DTA mutations in hematological neoplasms and define mutation-driven entities (myelodysplastic syndrome/MPN overlap; secondary acute myeloid) in comparison with entities defined by chromosomal fusions (chronic myeloid leukemia; myeloid/lymphoid neoplasm with eosinophilia).
引用
- Stengel A, Baer C, Walter W, et al. Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies. Blood Adv. 2021. PMID: 34570179. doi:10.1182/bloodadvances.2021004668
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。